MX2022012415A - Formulaciones farmaceuticas transdermicas y/o topicas que comprenden cannabidiol y/o tetrahidrocannabinol para el tratamiento del dolor cronico. - Google Patents
Formulaciones farmaceuticas transdermicas y/o topicas que comprenden cannabidiol y/o tetrahidrocannabinol para el tratamiento del dolor cronico.Info
- Publication number
- MX2022012415A MX2022012415A MX2022012415A MX2022012415A MX2022012415A MX 2022012415 A MX2022012415 A MX 2022012415A MX 2022012415 A MX2022012415 A MX 2022012415A MX 2022012415 A MX2022012415 A MX 2022012415A MX 2022012415 A MX2022012415 A MX 2022012415A
- Authority
- MX
- Mexico
- Prior art keywords
- transdermal
- treatment
- cannabidiol
- tetrahydrocannabinol
- topical pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063012428P | 2020-04-20 | 2020-04-20 | |
| PCT/IB2021/000261 WO2021214545A1 (en) | 2020-04-20 | 2021-04-20 | Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012415A true MX2022012415A (es) | 2023-02-09 |
Family
ID=78270322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012415A MX2022012415A (es) | 2020-04-20 | 2021-04-20 | Formulaciones farmaceuticas transdermicas y/o topicas que comprenden cannabidiol y/o tetrahidrocannabinol para el tratamiento del dolor cronico. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20210346310A1 (enExample) |
| EP (1) | EP4110325A4 (enExample) |
| JP (1) | JP2023523155A (enExample) |
| CN (1) | CN115916184A (enExample) |
| AU (1) | AU2021259495A1 (enExample) |
| CA (1) | CA3178878A1 (enExample) |
| MX (1) | MX2022012415A (enExample) |
| WO (1) | WO2021214545A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| JP2022551730A (ja) | 2019-10-14 | 2022-12-13 | パイク セラピューティクス，インコーポレイテッド | カンナビジオールの経皮送達 |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| WO2022003623A1 (en) * | 2020-07-01 | 2022-01-06 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations for the treatment of multiple sclerosis |
| MX2023006561A (es) * | 2020-12-03 | 2023-07-06 | Pike Therapeutics Inc | Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer. |
| AU2022257344A1 (en) * | 2021-04-12 | 2023-10-26 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| AU2022260813A1 (en) * | 2021-04-22 | 2023-10-26 | Pike Therapeutics Inc. | Transdermal pharmaceutical formulations for the treatment of chronic pain |
| EP4366728A4 (en) * | 2021-07-08 | 2025-05-14 | Innocan Pharma Ltd. | COMPOSITIONS FOR THE TREATMENT OF DIABETIC SYMPTOMS |
| US20230059204A1 (en) * | 2021-08-03 | 2023-02-23 | Pike Therapeutics, Inc. | Transdermal micro-dosing delivery of pharmaceutical agents |
| US20250222012A1 (en) * | 2021-11-02 | 2025-07-10 | Schedule 1 Therapeutics, Inc. | Use of cannabinoid compositions for treating pain associated with small fiber neuropathy |
| US20240024253A1 (en) * | 2022-07-21 | 2024-01-25 | Pike Therapeutics Inc. | Continuous Drug Delivery Systems and Methods |
| US11826342B1 (en) * | 2022-09-27 | 2023-11-28 | Saaransh Mahna | Cannabidiol formulation for alleviating pain and a method of manufacturing |
| CN118045221B (zh) * | 2024-02-04 | 2024-07-19 | 广东云曌医疗科技有限公司 | 一种水凝胶敷料及其制备方法和应用 |
| WO2026018119A1 (en) * | 2024-07-16 | 2026-01-22 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2414933B (en) * | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| US20080112895A1 (en) * | 2006-08-04 | 2008-05-15 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| DK2176208T3 (en) * | 2007-07-30 | 2015-04-27 | Zynerba Pharmaceuticals Inc | Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof |
| WO2010127033A1 (en) * | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
| EP2424568A1 (en) * | 2009-04-29 | 2012-03-07 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
| PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
| US9408802B1 (en) * | 2012-03-22 | 2016-08-09 | Prosolus, Inc. | Seven day drug in adhesive transdermal delivery |
| US9095563B2 (en) * | 2013-09-26 | 2015-08-04 | Ronald D. Sekura | Topical treatments incorporating Cannabis sp. derived botanical drug product |
| US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
| US9375417B2 (en) * | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
| CA2976004C (en) * | 2015-02-05 | 2020-06-02 | Colorado Can Llc | Purified cbd and cbda, and methods, compositions and products employing cbd or cbda |
| BR112017018944A2 (en) * | 2015-03-02 | 2018-05-15 | Afgin Pharma, Llc | method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s) |
| WO2016144376A1 (en) * | 2015-03-10 | 2016-09-15 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
| US10272125B2 (en) * | 2015-09-14 | 2019-04-30 | Life Tech Global, Llc | Transdermal delivery of cannabidiol with other active moieties including cannabinoids |
| MX2018004034A (es) * | 2015-09-30 | 2018-12-19 | Edward Hoag George | Formulaciones topicas de analgesicos para alivio del dolor fabricacion y uso de los mismos. |
| JP2019537628A (ja) * | 2016-11-02 | 2019-12-26 | ティクン オラム リミテッドＴｉｋｕｎ Ｏｌａｍ ＬＴＤ | 併用療法 |
| US10702495B2 (en) * | 2017-02-20 | 2020-07-07 | Nexien Biopharma, Inc. | Method and compositions for treating dystrophies and myotonia |
| FR3064334B1 (fr) * | 2017-03-24 | 2021-05-14 | Dcns Energies | Presse-etoupe de traversee etanche d'un orifice d'une cloison |
| US12357604B2 (en) * | 2017-09-22 | 2025-07-15 | Inmed Pharmaceuticals Inc. | Topical formulations of cannabinoids and use thereof in the treatment of pain |
| CA3076929A1 (en) * | 2017-09-25 | 2019-03-28 | Canopy Health Innovations | Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia |
| IL292126B2 (en) * | 2018-01-12 | 2025-04-01 | Nutrae Llc | Cannabinoid formulations are formulated for oral administration |
| US20200138772A1 (en) * | 2018-07-09 | 2020-05-07 | Volker Berl | Stabilized formulations of cannabinoid compositions |
| US20210015740A1 (en) * | 2019-03-04 | 2021-01-21 | Michael Harvey Greenspan | Topical cannabinoid compositions, delivery systems, and uses for pain relief |
| EP3969054A4 (en) * | 2019-05-16 | 2023-09-06 | Aegis Therapeutics, LLC | COMPOSITIONS CONTAINING OIL-SOLUBLE DRUGS AND METHODS OF USING SUCH COMPOSITIONS |
-
2021
- 2021-04-20 US US17/235,314 patent/US20210346310A1/en not_active Abandoned
- 2021-04-20 MX MX2022012415A patent/MX2022012415A/es unknown
- 2021-04-20 EP EP21791920.8A patent/EP4110325A4/en not_active Withdrawn
- 2021-04-20 JP JP2022560857A patent/JP2023523155A/ja active Pending
- 2021-04-20 WO PCT/IB2021/000261 patent/WO2021214545A1/en not_active Ceased
- 2021-04-20 CA CA3178878A patent/CA3178878A1/en active Pending
- 2021-04-20 AU AU2021259495A patent/AU2021259495A1/en active Pending
- 2021-04-20 CN CN202180042209.2A patent/CN115916184A/zh active Pending
-
2025
- 2025-03-24 US US19/087,734 patent/US20250248948A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021214545A1 (en) | 2021-10-28 |
| AU2021259495A1 (en) | 2022-10-27 |
| EP4110325A1 (en) | 2023-01-04 |
| CN115916184A (zh) | 2023-04-04 |
| EP4110325A4 (en) | 2024-07-03 |
| CA3178878A1 (en) | 2021-10-28 |
| JP2023523155A (ja) | 2023-06-02 |
| US20210346310A1 (en) | 2021-11-11 |
| US20250248948A1 (en) | 2025-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521421897B1 (ar) | تركيبة تعتمد على جزء من نباتات طبية أو مستخلصاتها واستخداماتها ومنتجاتها | |
| Bhat et al. | Aloe vera: Nature's soothing healer to periodontal disease | |
| EP4110325A4 (en) | TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | |
| NZ703394A (en) | Compositions and methods for treating crohn’s disease and related conditions and infections | |
| CA2549550A1 (en) | Botulinum toxin therapy for skin disorders | |
| IN2014DN09817A (enExample) | ||
| Thaçi et al. | Importance of basic therapy in psoriasis | |
| WO2012135812A3 (en) | Treatment for dermatological pathologies | |
| BR0006024A (pt) | Composição para o tratamento de inflamação e dor em mamìferos | |
| MX2023005658A (es) | Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso. | |
| Niazi et al. | Topical treatment for the prevention and relief of nipple fissure and pain in breastfeeding women: A systematic review | |
| BR112023023398A2 (pt) | Usos de um conjugado anticorpo-droga em combinação com um inibidor de checkpoint imune e de uma quantidade eficaz de conjugado anticorpo-droga e um inibidor de checkpoint imune, método para tratar um paciente com câncer urotelial, e, composição farmacêutica | |
| CN104337916A (zh) | 一种手脚冰凉及脚气的中药药剂 | |
| Prakoeswa et al. | Efficacy of topical epigallocatechin gallate (EGCG) 1% on the healing of chronic plantar ulcers in leprosy | |
| MX2022002646A (es) | Formulacion de ruxolitinib para la reduccion de comezon en dermatitis atopica. | |
| MX2025013786A (es) | Composición farmacéutica tópica para piel para administración de óxido nítrico en combinación con otros agentes dermatológicos tópicos | |
| BRPI0417116A (pt) | usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação | |
| WO2020170033A8 (en) | Method for treatment of moderate to severe erythema symptoms in rosacea patients | |
| Sahib et al. | Effects of oral antioxidants on lesion counts associated with oxidative stress and inflammation in patients with papulopustular acne | |
| Marciano et al. | Tamanu oil in acne management: Potential anti-inflammatory and wound-healing properties for scar reduction | |
| US10835584B2 (en) | Systems for treating dermal inflammatory conditions | |
| WO2021050564A3 (en) | Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders | |
| BRPI1101039A2 (pt) | composiÇço farmacÊutica tàpica para prevenÇço e tratamento do prurido otolàgico, mÉtodo de tratamento e uso | |
| US20260034149A1 (en) | Enhanced salicylic acid and drug delivery for aqueous topical applications | |
| Bikowski | Barrier repair as an element of psoriasis management |